IGHE and asthma: The immunoglobulin E (IgE) is the central actor of the allergic pathophysiological pathway [11, 12], and omalizumab, an anti-IgE recombinant humanized monoclonal antibody that binds to circulating IgE, inhibits the allergic response in asthma.